VYNE Therapeutics Inc. (VYNE)

Market Cap	22.38M +9.0%
Revenue (ttm)	454,000 -25.0%
Net Income	-21.46M
EPS	-0.50
Shares Out	33.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,026
Open	0.6623
Previous Close	0.6766
Day's Range	0.6600 - 0.6823
52-Week Range	0.2805 - 1.9600
Beta	2.00
Analysts	Buy
Price Target	2.00 (+197.84%)
Earnings Date	May 15, 2026

About VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 25, 2018
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: VYNE
• Website: https://vynetherapeutics.com

Financial Performance

In 2025, VYNE Therapeutics's revenue was $570,000, an increase of 13.77% compared to the previous year's $501,000. Losses were -$26.48 million, -33.52% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for VYNE stock is "Buy." The 12-month stock price target is $2.0, which is an increase of 197.84% from the latest price.

Price Target

$2.0

(197.84% upside)

Analyst Consensus: Buy